Coherus Expands Portfolio with $65M Acquisition of Surface Oncology

Coherus Biosciences has announced its acquisition of Surface Oncology for up to $65m, which is expected to close in Q3 2023. The deal will see Surface shareholders receive Coherus Biosciences stock as consideration. This move is significant for Coherus, which is launching biosimilar Yusimry in July and currently markets biosimilars of Neulasta and Lucentis. The acquisition will provide Coherus a..